RE: Today's RNS6 Dec 2024 21:08
You're welcome, N, Q, M.
While these trends often highlight China’s push for self-reliance in key sectors like pharmaceuticals, and its protectionist policies could constrain GSK’s market opportunities, I am optimistic about Shingrix’s prospects. Its demonstrated effectiveness makes it a standout product, and I believe the Chinese market will ultimately recognise its value. Of course, the mad actions of Trump could easily put the Kibosh on us piggies in the middle.